BARINTHUS BIOTHERAPEUTICS PL (BRNS) Stock News

USA - NASDAQ:BRNS - US91864C1071 - ADR

1.36 USD

-0.1 (-6.85%)

Last: 10/10/2025, 9:13:07 PM

1.3304 USD

-0.03 (-2.18%)

After Hours: 10/10/2025, 9:13:07 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BRNS Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Halper Sadeh LLC - Mentions: DAY ETNB VRNT

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates DAY, BRNS, ETNB, VRNT on Behalf of Shareholders

4 days ago - By: Brodsky & Smith LLC - Mentions: ETNB VRNT DAY

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)

4 days ago - By: Benzinga - Mentions: RFL OMI XTLB ESPR ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

7 months ago - By: ACCESS Newswire

Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

8 days ago - By: Halper Sadeh LLC - Mentions: VECO VRNT

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VECO, BRNS, VRNT on Behalf of Shareholders

8 days ago - By: Kahn Swick & Foti, LLC

BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS

11 days ago - By: Benzinga - Mentions: SI ENTA DBVT INTS ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 days ago - By: Halper Sadeh LLC

BRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Barinthus Biotherapeutics plc Is Fair to Shareholders

12 days ago - By: Stocktwits

Barinthus Biotherapeutics To Merge With Privately-Held Clywedog Therapeutics

12 days ago - By: Barinthus Biotherapeutics

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases

12 days ago - By: Barinthus Biotherapeutics

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases

2 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments

2 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments

4 months ago - By: ACCESS Newswire - Mentions: MNRG.CA OPHC XHLD ROLR ...

Q2 Virtual Investor Summit: Presentations Available Now

4 months ago - By: ACCESS Newswire

Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025

5 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

5 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

7 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

7 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

7 months ago - By: ACCESS Newswire - Mentions: DRTS GIFT VOXR FEMY ...

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

9 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

9 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

a year ago - By: Barinthus Biotherapeutics - Mentions: ABUS

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer